Outcome | Intervention | Â | Treatment As Usual | Â | Multi-level model analysis | p value |
---|---|---|---|---|---|---|
 | Change from baseline (95 % CI) | Change from baseline (95 % CI) | Between group change from baseline (95 % CI) |  | ||
CDI - 2 | Â | Â | Â | Â | ||
 6 weeks | −5.21 (−8.29, −2.14) | −2.64 (−5.92, 0.63) | −2.57 (−6.82, 1.68) | 0.23 | ||
 6 months | −8.63 (−12.15, −5.12) | −3.82 (−7.53, −0.12) | −4.81 (−9.49, −0.12) | 0.03 | ||
EQ-5D-5Â L | Â | Â | Â | Â | ||
 6 weeks | 0.04 (−0.48, 0.57) | −0.33 (−1.07, 0.42) | 0.37 (−0.53, 1.28) | 0.42 | ||
 6 months | 0.06 (−0.47, 0.59) | −0.30 (−1.02, 0.41) | 0.36 (−0.52, 1.26) | 0.41 | ||
EQ-VAS | Â | Â | Â | Â | ||
 6 weeks | 5.59 (−1.08, 12.26) | 3.65 (−3.14, 10.44) | 1.94 (−7.76, 11.64) | 0.69 | ||
 6 months | 6.10 (−1.49, 13.69) | 5.40 (−3.29, 14.09) | 0.69 (−10.2, 11.60) | 0.89 | ||
LTEQ | N | (%) | N | (%) | Probability difference between groups (95Â % CI)* | Â |
6Â weeks | 36 | Â | 28 | Â | Â | Â |
Insufficient active | 12 | (33) | 9 | (32) | −0.02 (−0.19, 0.23) | 0.87 |
Moderately active | 11 | (31) | 13 | (46) | −0.0 (−0.02, 0.02) | 0.91 |
Active | 13 | (36) | 6 | (22) | −0.02 (−0.23, 0.19) | 0.86 |
6Â months | 25 | Â | 17 | Â | Â | Â |
Insufficient active | 18 | (78) | 15 | (88) | −0.23 (−0.53, 0.07) | 0.10 |
Moderately active | 0 | (0) | 1 | (6) | 0.11 (−0.03, 0.25) | 0.09 |
Active | 7 | (28) | 1 | (6) | 0.12 (−0.05, 0.29) | 0.14 |